This Annual Report covers the SNO 2013 fiscal year, from July 1st, 2012 through June 30, 2014.
Dear Esteemed Colleagues,

I am honored to provide an update of SNO's key efforts during the past year. Suffice to say, it has been a busy year. Foremost, allow me to acknowledge that our efforts would not be successful without key input from my predecessor, Ken Aldape, the hard work of the SNO administrative staff led by Chas Haynes, and the support of our SNO Partners.

A critical SNO leadership priority remains making our Annual Meeting as productive and informative as possible. The 2013 SNO meeting, which integrated with the 4th Quadrennial World Federation of Neuro-Oncology (WFNO) meeting, was our most successful to date as reflected by record attendance (nearly 2100!), special thanks to Mitch Berger who served as overall Chair and Susan Chang for her tireless and invaluable efforts. Michael Weller takes over the WFNO reigns, and is actively planning the next international meeting (2017 - Zurich, Switzerland).

The SNO 2014 annual meeting combines an exciting program, thanks to the efforts of co-chairs Patrick Wen and Gelareh Zadeh, with a very attractive venue in Miami Beach. Special thanks also to Burt Nabors, Terri Armstrong, David Schiff, Alisdair Rooney and Eudocia Quant-Lee for organizing an outstanding Education Day program. I’d like to highlight some new features to this year’s meeting, including more sunrise sessions, a format of three concurrent sessions (all prior meetings have had only two), a significant increase in oral presentations via a new “rapid oral reports” category, and the use of electronic abstracts, which will be accessible during the entire meeting via strategically placed kiosks. After the meeting, please give us your feedback on these modifications or provide other suggestions so that we can make the 2015 meeting even more effective.

Another priority this year has been to better utilize technology advances to further promote the activity and collaboration of SNO members. An exciting update of the SNO website has just been unveiled which also includes seamless access to a companion member communication platform. Special thanks to Chas Haynes and Eric Sulman for their hard work bringing these efforts to fruition.

Another area of growth has been our journals. Neuro-Oncology Practice was launched successfully in the past year, thanks to many, and in particular, Susan Chang, overall Editor-in-Chief. Leadership of Neuro-Oncology transitioned successfully to Patrick Wen who has implemented several improvements and new features.

Finally, a key priority has been expanding SNO’s global role. The international outreach committee, led by Gelareh Zadeh, has initiated an effort to support a locally organized neuro-oncology conference in a global region just developing formal neuro-oncology societies and integrative research efforts. Matching funds to support this effort are being provided by the SNO Foundation and the University of Toronto, with a goal of conducting the first conference within the next year.

Looking ahead to 2015, there is much to do. SNO leadership remains committed to advancing our Society with an overall goal of improving outcome for CNS tumor patients.

Respectfully,

David A. Reardon, MD
Dear Society Members,

It is with great pleasure that I submit this 2014 Annual Report to the members and friends of the Society for Neuro-Oncology. This year was a productive year for the Society, with launch of several new initiatives that support our mission of fostering high-quality research, education and collaborative opportunities for all those involved in the research and treatment of CNS tumors.

Certainly a highlight for SNO in 2014 was the honor of hosting the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) in San Francisco. As you will read further in this Annual Report, the WFNO meeting was a remarkable event, showcasing research from investigators from around the globe, and breaking all previous records for both abstract submission and attendance. The next WFNO will be held in 2017 in Zurich, Switzerland, and SNO looks forward to assisting our colleagues from the European Association of Neuro-Oncology to ensure that meeting is equally successful.

This year SNO also participated in a number of collaborative events and initiatives. As part of the Jumpstarting Brain Tumor Drug Development Coalition, SNO participated in the development of guidance for sponsors of brain tumor clinical trials. SNO is indebted to the National Brain Tumor Society for their leadership in this important initiative. Also in 2014, SNO organized a well-attended Neuro-Tumor Club event during the annual conference of the American Association of Cancer Researchers, held jointly organized education sessions with the American Academy of Neurology at our respective meetings, and organized special SNO sessions at the annual meetings of the Asian Society for Neuro-Oncology and European Association of Neuro-Oncology.

And new this year, SNO began a collaboration with the Cochrane Group to provide training opportunities to further our understanding of brain tumors.

In partnership with Oxford University Press, SNO members began receiving our second journal, Neuro-Oncology Practice, this year. Already off to a positive start, this new resource is addressing a range of topics on the applied and practical aspects of neuro-oncology. The new title is intended to compliment the editorial content of our flagship publication, Neuro-Oncology, which remains the seminal journal in our field. Detailed information on both journals is provided further in this Annual Report.

Looking ahead, under the leadership of SNO President David Reardon, the Society has embarked on an ambitious plan to invest in new technology to add further value to our annual meeting and our internet presence. Members can look forward to exciting new advances in SNO organized conferences, social media and the launch of a web-based communications platform.

There is no doubt that SNO’s progress this year would not have been possible without the dedicated efforts of our board of directors, committee chairs and members. I would also like to especially thank Jan Esenwein, Linda Greer, Megan Bell, Kristin Odom and Elizabeth Haynes for their support of our mission and hard work. The Society continues to move in a positive direction as we seek to improve the care and treatment of patients with brain tumors.

J. Charles Haynes, JD
SNO Executive Director
Dear Society for Neuro-Oncology Members and Supporters,

On behalf of the SNO Foundation, I am pleased to report that the Society’s financial position has never been stronger.

As the fundraising arm of SNO, the Foundation partners with the Society to support educational resources to better assist the clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults.

With the help of a generous grant from the National Brain Tumor Society, the Foundation was able to make a significant and strategic investment in our new journal, *Neuro-Oncology Practice*. We expect this new publication to become an important resource on clinical best practices and patient care. This journal will provide readers with the latest developments in clinical decision-making, molecular profiling, advanced imaging, symptom management, quality of life, psychosocial support and a range of other important topics on the applied and practical aspects of neuro-oncology. Edited by Susan Chang, the title will be published initially on a quarterly basis and will be included as a value added benefit of membership in the Society.

In addition to strategic investments like the new journal, the support of our corporate and nonprofit partners, as well as the generosity of our members, allows the Foundation to contribute to improving SNO’s core elements. This includes financial support for:

- The editorial offices of our official journal, *Neuro-Oncology*,
- Key programmatic elements of the annual meeting including Town Halls and Keynotes,
- Travel scholarships to the annual meeting
- Research awards and new initiatives for Young Investigators
- Improvements in meeting technology, and
- International outreach efforts

We are grateful to the non-profit associations and corporate donors who support the Foundation at the highest level as members of the Partner’s Advisory Council. The Council has direct access to the SNO Board of Directors and Foundation Executive Board on a regular basis. The 2013-2014 members of the Council include Genentech, the National Brain Tumor Society, Novocure, Merck, the Pediatric Brain Tumor Foundation, and the Sontag Foundation. This year we are pleased to welcome Celldex and Bristol Myers Squib as our newest Advisory Council members.

The SNO Foundation remains committed to supporting important new initiatives and we continue to look ahead for additional opportunities to realize our common mission — finding a cure for brain tumors.

Very truly yours,

Mark R. Gilbert, MD (Foundation President)
Mitchel S. Berger, MD
Susan M. Chang, MD
Victor A. Levin, MD
The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology was held in conjunction with the 18th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology on November 21-24, 2013 in San Francisco, CA. The meeting enjoyed record attendance of close to 2100 registrants from 46 different countries.

We congratulate meeting chair, Dr. Mitchel Berger, for composing a comprehensive program which highlighted cutting-edge laboratory and clinical research. Special thanks are also extended to the scientific planning committee which was comprised of members from each of the three leading neuro-oncology societies, including Koich Ichimura & Ryo Nishikawa (ASNO), Riccardo Soffietti & Michael Weller (EANO) and Susan Chang & Russell Pieper (SNO). The meeting provided an enthusiastic environment for the exchange of ideas among clinical and laboratory scientists involved in the research, diagnosis, care and treatment of patients with central nervous system tumors.

**Education Day**

The Education Day on Thursday, November 21 was entitled From Drug Discovery to Clinic and reviewed the various aspects of clinical development of agents that range from preclinical testing, pharmacokinetic and pharmacodynamic considerations, first in man studies, and the challenges of phase 0-III clinical trials. Alternate concurrent sessions appraised the specific challenges of clinical design and specific pathways that are being evaluated in the preclinical arena. Also featured was a Quality of Life Session with modules focused on Palliative Care, Symptom Management, and Pediatric Quality of Life.

**WFNO Quadrennial and SNO Annual Meeting**

The meeting built on the traditional SNO format and presented top-scoring abstracts and meet-the-expert sessions. The Scientific Meeting began Friday, November 22 with sunrise sessions followed by the start of the first general session. The four Sunrise Sessions were on the following topics: 1) Maximal Safe Resection of Glioma - Current Techniques, 2) Pediatric Genomics Update, 3) Innovative QOL Programs in the Clinic Setting, 4) Metabolic Imaging. After the sunrise sessions, the first plenary session started with an official meeting welcome by Dr. Mitchel Berger followed the Victor Levin Lecture by Monika Hegi and Roger Stupp. Dr. Kenneth Aldape then delivered his Presidential Address followed by the EANO Keynote Address by Stefan Pfister, MD, PhD, entitled Translating next generation diagnostics into next generation treatment.

A Young Investigators Luncheon Roundtable was held at noon on Friday at which trainees and early phase independent investigators participated in informal discussions with senior investigators at roundtables organized into a variety of different areas. Lunch was followed by afternoon concurrent sessions including 1) Pathology and Genomic and 2) Adult Clinical Sciences. The next set of concurrent sessions included 1) Angiogenesis and Invasion and 2) Pediatric Clinical Sciences. Friday evening, a special “Townhall Meeting” reviewed the

---

**WFNO Abstract Award Winners**

**ADULT CLINICAL RESEARCH AWARD**

- Mark Gilbert
  *RTOG 0825: Primary outcome results from a phase III randomized, placebo controlled trial evaluating bevacizumab in newly diagnosed glioblastoma*

- Olivier L. Chinot
  *Final efficacy and safety results from AVAglio, a phase III trial of bevacizumab (BEV) plus temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma*

**ADULT QUALITY OF LIFE AWARD**

- Vinai Gondi
  *Memory preservation with conformal avoidance of the hippocampus during whole-brain radiotherapy (WBRT) for patients with brain metastases: preliminary results of RTOG 0933 Supported by the Sontag Foundation*
results of the recent international randomized phase III trials evaluating the use of antiangiogenic strategies for newly diagnosed and recurrent glioblastoma session.

Saturday Sunrise Sessions featured the following topics: Session 1, WHO Classification of Tumors – Update; Session 2, Overview of GWAS and Potential for International Collaboration; Session 3, Immunological Strategies in Neuro-Oncology; Session 4, Asymmetric Cell Division-Avenues for Research and Clinical Applications; Session 5, Joint AAN Session: Controversies in Neuro-Oncology. After the sessions a mini-symposium on Low Grade Gliomas was held and trailed by the ASNO Keynote Address by Do-Hyun Nam, MD, PhD, entitled Personalized targeted therapeutics based on the genomic characterized patient derived model (Avatar) system. Up next, award winning abstracts were presented and they were followed by the SNO Keynote address by Frank McCormick, PhD, entitled New Ways of Targeting Ras.

The first of its kind mid-level faculty networking luncheon was held at noon on Saturday with the intent of forming a horizontal mentoring group. After lunch we witnessed the first set of Saturday afternoon concurrent session: 1) Cell Biology and Signaling, 2) Molecular Epidemiology and Biomarkers. The second set of concurrent sessions included 1) Pediatric Basic and Translational Research and 2) Neurocognitive Outcomes and Quality of Life. A poster session was organized after the oral sessions concluded for the day. That evening, the SNO Gala Dinner, at San Francisco City Hall, was the social highlight of the meeting at allowed us to recognize the important service of those who make the meeting possible.

The Sunday, November 24th Sunrise Sessions included 1) Brain Metastases; 2) Minimizing Side Effects From Radiation; 3) Tumor Associated Epilepsy; 4) Microgliia. The sunrise sessions were followed by concurrent meetings on Metabolic Pathways/Stem Cells and Imaging and RANO Update. The last concurrent sessions were 1) Preclinical Therapeutics and 2) Biologic/Immunologic Therapies followed by the meeting’s adjournment.
The year 2014 saw Dr. Patrick Wen of Dana-Farber Cancer Institute successfully take the helm at *Neuro-Oncology* as Editor-in-Chief, and thus the official journal of the Society for Neuro-Oncology (SNO) continued the well-established trajectory led since 2007 by Dr. W. K. Alfred Yung, and before that since 1999 by Founding Editor Darell D. Bigner. Two of the outstanding and dedicated Executive Editors, Dr. C. David James representing the Society for Neuro-Oncology (SNO) from the University of California, San Francisco, and Dr. Michael Weller, representing the European Association of Neuro-Oncology (EANO) from the University of Zurich, stepped down from their roles to be replaced by Dr. Kenneth Aldape from the MD Anderson Cancer Center, representing SNO, and Dr. Riccardo Soffietti from the University of Torino, representing EANO. Fortunately Dr. Ryo Nishikawa remained the Japan Society for Neuro-Oncology (JSNO) Executive Editor, providing the Journal with continued invaluable experience and counsel.

The Journal said goodbye to its former editorial office support team based in the Department of Scientific Publications at the University of Texas MD Anderson Cancer Center, and welcomed its new Managing Editor, Dr Elizabeth Martinson.

Given the diverse subspecialties within the field, 2014 saw *Neuro-Oncology* recruit a very talented group of Associate Editors:

- Terri Armstrong from MD Anderson Cancer Center (quality of life),
- Karla Ballman from Mayo Clinic (statistics),
- Ennio Chiocca from Brigham and Women's Hospital and Dana-Farber Cancer Institute (neurosurgery),
- Frank Furnari from the Ludwig Institute of Cancer Research (basic and translational science),
- Monika Hegi from the University of Lausanne (basic and translational science),
- Mark Kieran of the Dana-Farber Cancer Institute and Boston Children's Hospital (pediatric neuro-oncology),
- Mitesh Mehta from the University of Maryland (radiation oncology),
- Whitney Pope from the University of California, Los Angeles (neuroradiology),
- Hideyuki Saya from Keio University (basic science),
- David Schiff from the University of Virginia (neuro-oncology),
- and Wolfgang Wick from the University of Heidelberg (neuro-oncology and translational science).

There have been changes behind the scenes too, as the Journal said goodbye to its former editorial office support team based in the Department of Scientific Publications at the University of Texas MD Anderson Cancer Center, and welcomed its new Managing Editor, Dr Elizabeth Martinson.

Continued popularity with authors

In spite of an increasingly competitive publishing arena in oncology, with more journals vying for good manuscripts, *Neuro-Oncology* continues to see more submissions than prior years; if the submission trend for 2014 continues past that of September the Journal estimates more than 700 new submissions this year, together with X revised submissions after peer review.

*Neuro-Oncology* now achieves much faster peer-review of manuscripts with the mean time to first decision down to 33 days for the first half of 2014, compared with 2013 when this time was 42 days. Dr. Wen plans a focus on timeliness of peer review as an editorial objective for 2015, while not compromising the quality of the peer review. Fast-track peer review will be offered to key manuscripts identified by the editorial team. Another author benefit shortly to be introduced to the Journal is faster online publication of accepted manuscripts: *Neuro-Oncology* will move towards initial publication of the authors' accepted manuscript within a few days of acceptance – thus getting key findings and data out earlier to readers in a citable form.

Figure 1. New manuscript submissions to *Neuro-Oncology*
And, of course, abstracts for the Society’s own successful conference in Miami will publish in the Journal – for which over 900 abstracts were submitted.

**Strong Impact Factor**

While Neuro-Oncology didn’t maintain its record high Impact Factor of 6.180 for 2012, the Journal remains the top specialist journal in the field with a 2013 Impact Factor of 5.286, ranking the Journal at 18 of 194 in Clinical Neurology and 30 of 202 Oncology titles. Of note, the Journal’s only direct competitor Journal of Neurooncology registered an Impact Factor of 2.787 – also down on prior year. [Figure 2]

**Continued growth in readership**

As the membership of SNO continues to grow to more than 1800 members, so does the circulation and readership of the Journal. In addition, approximately 700 EANO members have access to the Journal online as part of their EANO membership. So far in 2014, there have been more than 40,000 full-text downloads per month on average. Such growth in usage of the Journal online serves to show how valuable the articles are to readers, and is also a reflection of the Journal’s wider visibility into several thousand institutes globally. [Figure 3]

In summary, 2014 has been a year of editorial change for Neuro-Oncology, but at the same time clearly it has been a year of unrivalled success. Supported by a refreshed editorial team, by the members of its Editorial Board, by its numerous peer and statistical reviewers to whom the Journal is indebted, and by its publisher – Oxford University Press – Neuro-Oncology looks forward to continuing to serve the field and to help SNO meet its goal of advancing multidisciplinary research and education in neuro-oncology.
ADVANCING PROFESSIONAL EXCHANGE

SNO strives to reach out and collaborate with sister groups that share our scientific goal of better understanding CNS malignancies. Highlights of these interorganizational efforts from 2014 are described below.

**Annual Neuro-Tumor Club Meeting**
The 20th Annual Neuro-Tumor Club Dinner Meeting took place on April 7, 2014, in San Diego, California. This meeting, for brain tumor researchers attending the Association of Cancer Researchers (AACR) Annual Meeting, was organized by the Society for Neuro-Oncology with the support of Genentech, Novocure and the National Brain Tumor Society. Frank Furnari of the Ludwig Institute for Cancer Research, University of California, San Diego, and Shi-Yuan Cheng of Northwestern University, served as co-chairs for the dinner.

The event drew approximately 150 investigators from diverse disciplines relevant to brain tumor research, and was very successful in strengthening existing personal research connections and collaborations, generating new associations and presenting the group with updates in topics important to brain tumor research. Forty abstracts were received of uniformly high quality. Submissions came from eight countries and were reflective of cutting edge, thought-provoking basic and translational research in the field of neuro-oncology.

**SNO Participates in Brain Tumor Clinical Trial Endpoints Workshop**
Hosted by the Jumpstarting Brain Tumor Drug Development Coalition (which includes as members the Accelerate Brain Cancer Cure, the Musella Foundation for Brain Tumor Research & Information, the National Brain Tumor Society, and the Society for Neuro-Oncology), experts representing the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI), medical imaging companies, contract research organizations, leading biopharmaceutical companies, and medical academic research organizations, addressed how to overcome variables in medical imaging, which currently hinder the ability to accurately assess brain tumor response to investigational therapies, thus slowing drug development for this vulnerable patient population.

The Workshop featured presentations and panel discussions, as well as facilitated audience-panel deliberations on topics including current brain tumor imaging protocols in multicenter trials, emerging techniques and technologies in brain tumor imaging, and the use of imaging measurements of tumor progression and tumor response in clinical trials. From these conversations, a final group discussion drove the creation of an action plan for the community to follow in order to improve the accuracy and consistency of imaging data, and to launch a coordinated effort to accelerate brain tumor therapy approvals using imaging as a criteria. SNO appreciates the leadership of the NBTS on this initiative and looks forward to working with the Coalition to develop guidance materials for the standardization of image acquisition and analysis within brain tumor clinical trials. The goal is for this guidance to be adopted by all sponsors of brain tumor clinical trials, as well as to demonstrate that the brain tumor research and clinical trial environment is innovative, adaptive, and ready for further investment by academia, pharmaceutical companies, and the government.

**Cochrane Collaboration Review Course Grants**
As part of a joint initiative with the Cochrane Collaboration, review training grants have been awarded to the following SNO members: Caroline Chung, Princes Margaret Cancer Center, Toronto, Ontario (Treatment of radiation brain necrosis after radiotherapy or radiosurgery) Luluel Khan, University of Toronto, Toronto, Ontario (Radiation dose escalation for high grade glioma) and John Villano, University of Kentucky, Louisville, Kentucky (PCV for refractory high-grade gliomas).

SNO congratulates these successful applicants on this prestigious recognition and opportunity to expand our understanding of CNS tumors and looks forward to future initiatives with the Cochrance Group.
SNO LAUNCHES NEW JOURNAL: NEURO-ONCOLOGY PRACTICE

With the generous support of the National Brain Tumor Society, the Society of Neuro-Oncology and Oxford University Press have collaborated to launch a new quarterly journal, Neuro-Oncology Practice, as a complement to Neuro-Oncology.

Edited by Dr. Susan Chang, Director of the Division of Neuro-Oncology at UCSF, in San Francisco, California, Neuro-Oncology Practice launched in-print and online early in 2014.

Neuro-Oncology Practice fills a need for practical and educational content, and provides the multidisciplinary field of neuro-oncology professionals, such as physicians, nurses, physical and occupational therapists, palliative care specialists, and neuropsychologists, with clinical information to enhance patient care, quality of life, psycho-social support, and management of co-morbid conditions.

The Journal’s aims include:
• applying new trial results to improve standards of patient care,
• translating scientific advances, such as tumour molecular profiling and advanced imaging, into clinical treatment decision-making and personalized brain tumour therapies, and
• raising awareness of basic, translational, and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues, and caregiving

Distinguished co-editors from the various international neuro-oncology societies – Jeffrey Wefel (SNO editor), Wolfgang Grisold (EANO Editor), and Rakesh Jalali (ASNO Editor) – work with Dr. Chang to ensure the highest quality of papers selected for publication. They are joined by a multidisciplinary and global team of Associate Editors:
• Heather Conklin – Pediatric outcomes
• Martin Klein – Neuropsychological / Neurocognitive outcomes
• Antoinio Omur – Paraneoplastic syndromes
• Stephanie Shook Pugh – Biostatistics
• Martin Taphoorn – Palliative Care / Hospice
• Michael Weller – Application of clinical trials, Biomarkers and Imaging

The leadership of the journal is supported by a distinguished Editorial Board listed on the SNO website. The Journal is already a success, having published its first three issues on time, with the fourth almost on the presses. SNO’s members and the wider field now have access to a total of 29 (as at Sept 2014) additional high-quality papers to help improve patient care and outcomes in neuro-oncology. Initial feedback from readers to the editorial team has been great.

For the moment, the Journal is too young to be indexed by Medline, but it will be submitted for indexing early next year. It is, however, already indexed by Google/Google Scholar—and we know that in reality Google drives most online journal usage (even for Medline indexed journals). 2015 should see further exciting developments for Neuro-Oncology Practice as it settles into this important niche within our field.
Society For Neuro-Oncology
Financial Highlights
Fiscal Year Ended June 30, 2013

The following financial highlights are prepared by management of Society for NeuroOncology for the fiscal year ended June 30, 2013 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor’s Report will be posted at www.soc-neuro-onc.org.

Statement of Financial Position highlights, as of June 30, 2013

Cash and cash equivalents $1,400,000
Investments 676,000
Contributions receivable 25,000
Endowment assets 178,000
Other assets 65,000

Total assets $2,365,000

Liabilities $229,000
Net assets 2,136,000

Total liabilities and net assets $2,365,000

STATEMENT OF ACTIVITIES HIGHLIGHTS, FOR THE FISCAL YEAR ENDED JUNE 30, 2013

Total revenues and other support $2,103,000
Total program and supporting service expenses 1,888,000

Change in net assets $215,000
Society For Neuro-Oncology

Financial Highlights

Fiscal Year Ended June 30, 2014

The following financial highlights are prepared by management of Society for Neuro-Oncology for the fiscal year ended June 30, 2012 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor's Report will be posted at www.soc-neuro-onc.org.

Statement of Financial Position highlights, as of June 30, 2014

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,844,000</td>
</tr>
<tr>
<td>Investments</td>
<td>$839,000</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>$85,000</td>
</tr>
<tr>
<td>Endowment assets</td>
<td>$217,000</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$2,985,000</strong></td>
</tr>
<tr>
<td>Liabilities</td>
<td>$482,000</td>
</tr>
<tr>
<td>Net assets</td>
<td>$2,503,000</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$2,985,000</strong></td>
</tr>
</tbody>
</table>

STATEMENT OF ACTIVITIES HIGHLIGHTS, FOR THE FISCAL YEAR ENDED JUNE 30, 2014

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues and other support</td>
<td>$2,413,000</td>
</tr>
<tr>
<td>Total program and supporting service expenses</td>
<td>$2,015,000</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td><strong>$398,000</strong></td>
</tr>
</tbody>
</table>
Executive Director
J. Charles Haynes, JD

Chief Administrative Officer
Jan Esenwein

Membership Manager
Linda Greer

Marketing and Exhibits Coordinator
Megan Bell

Administrative Coordinator
Elizabeth Haynes

Communications Coordinator
Kristin Odom

Bookkeeper
Martha Maloch

Society for Neuro-Oncology
4617 Birch Street
Bellaire TX 77401
tel 713.349.0952
tax 832.201.8129

www.soc-neuro-onc.org
OFFICERS, BOARD OF DIRECTORS AND COMMITTEES

President
Kenneth Aldape, MD

Vice President
Michael Vogelbaum, MD, PhD

Secretary-Treasurer
E. Antonio Chiocca, MD, PhD

Board of Directors
Eric Bouffet, MD
Sherry Fox, PhD
Mary Lovely, PhD
Andrew Parsa, MD
David Peereboom, MD
Russell Pieper, PhD
David Reardon, MD
Jann Sarkaria, MD
Michael Taylor, MD, PhD

Past President
Frederick Lang, MD

Foundation Board
Mark R. Gilbert, MD (President)
Victor A. Levin, MD (SNO Founder)
Mitchel S. Berger, MD
Susan Chang, MD

Journal Editor in Chief
W. K. Alfred Yung, MD

Journal Executive Editor (SNO)
C. David James, PhD

SNO STANDING COMMITTEES

The Audit Committee shall consist of the Chair, Vice President of the Society and the Secretary-Treasurer. The committee shall have the responsibility of overseeing annual internal audit of the Society’s financial affairs, and conveying the audit to the President and the Board, who may approve review of the audit by external committees as needed. The committee shall also advise and make recommendations to the Board of Directors based on findings of such audits. The Audit Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.
Chair: Gene Barnett

The Awards Committee shall consist of the Chair, the Scientific Program Chair and other members who shall develop criteria for all SNO meeting awards, annually review meeting award candidates, and forward to the Board a list of awards and award recipients to be honored at the Annual Meeting. The Awards Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.
Chair: David Eisenstat

The Bylaws Committee shall consist of the Chair, the Secretary/Treasurer (ex officio) and two other members who shall review the Bylaws annually and make recommendations for revision as necessary. Members of this committee shall review any proposed changes and advise the Board of Directors on proposed revisions. The Bylaws Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.
Chair: David Schiff

The Communications Committee shall consist of the Chair, the Secretary/Treasurer (ex officio) and other members who shall be responsible for the news section of the Society’s official journal and the Society’s newsletter, and will have the responsibility of advising the Board of Directors on the Society’s internal and external communications. The Communications Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.
Chair: Nicholas Butowski

The Future Sites Committee shall consist of the Chair, a previous Chair of the Annual Meeting Committee and two other members who shall review potential sites and hotel proposals for future meetings, evaluating size and appropriateness of meeting space, availability and quality of sleeping rooms, proposed room rates, and recommends to the Board the most appropriate venue. The Future Sites Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.
Co-Chairs: Jonathan Knisely and Mark Gilbert
The International Outreach Committee shall consist of the Chair and other representative international members recommended by the Chair or President, as approved by the Board of Directors. The committee shall have the responsibility of advising and making recommendations to the Board of Directors on international affairs, promoting international membership, and shall develop the criteria and review candidates for SNO international outreach travel grants and fellowships. The International Outreach Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. 

*Chair: Gelareh Zadeh*

The Annual Meeting Committee shall consist of a Scientific Program Chair, Education Day Chair, the immediate past Chairs of the Annual Meeting Committee and other members representing each of the SNO specialty areas who shall supervise and coordinate all aspects of the next SNO Scientific Meeting and Education Day. The Meeting Committee members shall serve a one-year term and such term may be renewable at the discretion of the President. 

*Chair: Patrick Wen and Gelareh Zadeh*

The Membership Committee shall consist of the Chair and four members who shall make recommendations to the Board of Directors concerning efforts to promote and increase membership in Society. They shall also review and vote on all applicants for membership and shall evaluate a member's professional conduct as requested by a majority of the Board of Directors. The Membership Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. 

*Chair: Manmeet Ahluwalia*

The Website Committee shall consist of the Chair and other members who shall have the responsibility of coordinating and overseeing the Society’s official website. The Website Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. 

*Chair: Erik Sulman*

The Young Investigators Committee shall consist of the Chair and other members who shall have the responsibility of advising the Board of Directors on issues pertaining to graduate students, residents, fellows and members within the first five years of their initial clinical or academic appointment. The Young Investigators Committee shall also have the responsibility of coordinating the SNO Grant Review initiative. The Young Investigators Committee members shall serve a two-year term and such term may be renewable at the discretion of the President. 

*Chair: Jason Huse*
SNO SUPPORTERS

Platinum Level
Bristol-Myers Squibb
Celldex Therapeutics
Genentech
Merck
Novocure
National Brain Tumor Society
Pediatric Brain Tumor Foundation
Sontag Foundation

Benefactors
CERN Foundation
McFeeters Brain Tumor Research Centre, University of Toronto

Supporters
Abbvie
Alan and Susan Hudson Chair in NeuroOncology, University Health Network, Toronto
American Brain Tumor Association
Brain Tumour Foundation of Canada
Chris Elliott Fund
Cure Brain Cancer Foundation
Elekta
Northwest Biotherapeutics

International Outreach & Guha Fund
Children’s Brain Tumor Foundation
Sontag Foundation
SNO Foundation
Victor Levin Founders Society

Individual Donations and Levin Society
Lewis Ward
in memory of Durward Kenneth Stutts, Jr.
Mrs. Carol S. Gold
Victor and Ellen Levin

Neuro-Tumor Club Meeting
Genentech
National Brain Tumor Society
Novocure

Exhibitors
AbbVie
American Brain Tumor Association
Arbor Pharmaceuticals
BrainLab
Bristol-Myers Squibb
Celldex Therapeutics
CERN Foundation
Chris Elliott Foundation and Musella Foundation
Elekta
Foundation Medicine
Genentech
International Brain Tumour Alliance
IsoRay Medical
Karl Storz
LabCorp
Magforce AG
Monteris
National Brain Tumor Society
Nicki Leach
NICO Corporation
Northwest Biotherapeutics, Inc.
Novartis
Novocure
Oxford University Press
Sigma Tau
Stemline
Synaptive Medical
The Sontag Foundation
Tocagen
UF Health Neurosurgery
Mission
SNO fosters multidisciplinary neuro-oncology research and education to improve patient outcomes.

Vision
SNO is the pre-eminent multidisciplinary society involved in state-of-the-art neuro-oncology research, education, and patient care.

SNO Members
- Radiation Oncology 11%
- Neurosurgery 19%
- Neuro-oncology 33%
- Pathology 5%
- Medical Oncology 6%
- Pediatric Oncology 5%
- Radiology 1%
- Psychology 1%
- Pharmacology 1%
- Epidemiology 1%
- Statistics 1%
- Public Health 1%
- Foundation 1%
- Industry 1%
- Other 3%
- Neurosurgery 19%